|
FR3092115A1
|
|
fluorescent GTP analogues and use
|
|
FR3092172A1
|
|
Method for measuring the modulation of activation of a G protein coupled receptor with GTP analogues
|
|
FR3084365A1
|
|
SINGLE DOMAIN ANTIBODIES BOUND WITH G ALPHA PROTEIN
|
|
CA3070777A1
|
|
Method for measuring modulation in the activity of a g protein-coupled receptor
|
|
CN110914259A
|
|
Novel water-soluble mono-and di-branched complexing agents and corresponding lanthanide complexes
|
|
FR3067712A1
|
|
Novel hydrosoluble trimethoxyphenyl pyridine-like complexants and corresponding lanthanide complexes
|
|
FR3045053A1
|
|
TRIAZAPYRIDINOPHANE WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING FLUORESCENT LANTHANIDE COMPLEXES
|
|
FR3032797A1
|
|
METHOD OF QUANTIFYING A PROTEIN OF INTEREST PRESENT IN A BIOLOGICAL SAMPLE
|
|
FR3000960A1
|
|
NOVEL WATER SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES
|
|
EP2717057A1
|
|
Morphine-6-glucuronide derivatives, immunogens and immunoassay
|
|
EP2756305A1
|
|
Method for determining the glycosylation of an antibody
|
|
FR2993668A1
|
|
Theranostic method based on the detection of her2-her2 dimers
|
|
FR2988174A1
|
|
METHOD FOR DETERMINING THE CAPACITY OF ANTIBODY TO MAINTAIN CELLS CLOSE TO EACH OTHER
|
|
EP2817614A1
|
|
Method for normalising the luminescence emitted by a measuring medium
|
|
EP2615461A1
|
|
Method for predicting a risk of increased mortality
|
|
FR2978149A1
|
|
Novel complexing agents and complexes of corresponding lanthanide, and their use as luminescent markers
|
|
FR2977674A1
|
|
Improved method of detecting and / or quantifying an analyte present at the surface of a cell
|
|
EP2464973A2
|
|
Method for predetermining the binding of a given compound to a membrane receptor
|
|
EP2087355A2
|
|
Method for the detection of post-translational modifications
|
|
EP1931997A2
|
|
Method of examining a biological process using a fret measurement
|
